Clinical Trials Browser

INDUSTRY × Interventional × Pathologic Complete Response × Clear all

Pathologic Complete Response, Ovarian Neoplasms

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

127 enrolled

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 3 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

22 enrolled 8 charts

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04934670 2024-08-27

2002

Phase 3 Terminated

12 enrolled 12 charts

Lymphoid

Pathologic Complete Response, Lymphoma, Follicular

NCT02789254 2023-12-28

FLYSYN-101

Phase 1/2 Completed

31 enrolled

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Leukemia, Myeloid, Acute

NCT04126590 2023-09-01

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Phase 1 Unknown

39 enrolled

Pathologic Complete Response

NCT00725283 2018-08-07

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

Phase 1 Completed

34 enrolled 10 charts

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Leukemia, Myeloid, Acute

NCT01520558 2017-06-29

CNDO-109-AANK for AML in First Complete Remission (CR1)

Phase 1/2 Unknown

12 enrolled 11 charts

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Phase 2 Completed

Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Clinical Trials

SOLO-1

REGAL

QUAZAR AML-001

ATHENA

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

2002

FLYSYN-101

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

CNDO-109-AANK for AML in First Complete Remission (CR1)

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy